Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus NASACORT HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus NASACORT HFA.
ARMONAIR RESPICLICK vs NASACORT HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators (e.g., cytokines, prostaglandins) and reducing nasal inflammation.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
55 mcg (1 spray) per nostril once daily; may increase to 110 mcg (2 sprays) per nostril once daily if needed. Maximum 440 mcg/day total.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Terminal elimination half-life is approximately 3.5 hours following intranasal administration, reflecting slow systemic absorption and prolonged local retention.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites and parent drug)
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid